Literature DB >> 21925855

TOR in the immune system.

Koichi Araki1, Ali H Ellebedy, Rafi Ahmed.   

Abstract

The target of rapamycin (TOR) is a crucial intracellular regulator of the immune system. Recent studies have suggested that immunosuppression by TOR inhibition may be mediated by modulating differentiation of both effector and regulatory CD4 T cell subsets. However, it was paradoxically shown that inhibiting TOR signaling has immunostimulatory effects on the generation of long-lived memory CD8 T cells. Beneficial effects of TOR inhibition have also been observed with dendritic cells and hematopoietic stem cells. This immune modulation may contribute to lifespan extension seen in mice with mTOR inhibition. Here, we review recent findings on TOR modulation of innate and adaptive immune responses, and discuss potential applications of regulating TOR to provide longer and healthier immunity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925855      PMCID: PMC3241972          DOI: 10.1016/j.ceb.2011.08.006

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  68 in total

Review 1.  Origins of CD4(+) effector and central memory T cells.

Authors:  Marion Pepper; Marc K Jenkins
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells.

Authors:  Sandrine Benhamron; Boaz Tirosh
Journal:  Eur J Immunol       Date:  2011-06-24       Impact factor: 5.532

3.  Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.

Authors:  Kan Cao; John J Graziotto; Cecilia D Blair; Joseph R Mazzulli; Michael R Erdos; Dimitri Krainc; Francis S Collins
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

4.  De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.

Authors:  Johnthomas Kang; Stephen J Huddleston; Joanne M Fraser; Alexander Khoruts
Journal:  J Leukoc Biol       Date:  2008-02-12       Impact factor: 4.962

5.  Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells.

Authors:  Masashi Ohtani; Shigenori Nagai; Shuhei Kondo; Shinta Mizuno; Kozue Nakamura; Masanobu Tanabe; Tsutomu Takeuchi; Satoshi Matsuda; Shigeo Koyasu
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

6.  HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.

Authors:  Lewis Z Shi; Ruoning Wang; Gonghua Huang; Peter Vogel; Geoffrey Neale; Douglas R Green; Hongbo Chi
Journal:  J Exp Med       Date:  2011-06-27       Impact factor: 14.307

7.  Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking.

Authors:  Linda V Sinclair; David Finlay; Carmen Feijoo; Georgina H Cornish; Alex Gray; Ann Ager; Klaus Okkenhaug; Thijs J Hagenbeek; Hergen Spits; Doreen A Cantrell
Journal:  Nat Immunol       Date:  2008-04-06       Impact factor: 25.606

8.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

9.  Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates.

Authors:  Surojit Sarkar; Vandana Kalia; W Nicholas Haining; Bogumila T Konieczny; Shruti Subramaniam; Rafi Ahmed
Journal:  J Exp Med       Date:  2008-03-03       Impact factor: 14.307

10.  The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells.

Authors:  Sokol Haxhinasto; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2008-02-18       Impact factor: 14.307

View more
  63 in total

Review 1.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  Targeted immunosuppression: no longer naïve.

Authors:  Robert S Hagan; Jonathan D Powell
Journal:  Clin Immunol       Date:  2011-10-25       Impact factor: 3.969

3.  Loss of translation: a stealth weapon against pathogens?

Authors:  Philippe Pierre; Evelina Gatti
Journal:  Nat Immunol       Date:  2013-12       Impact factor: 25.606

4.  [Immunogerontology - Research into aging].

Authors:  B Grubeck-Loebenstein
Journal:  Z Rheumatol       Date:  2015-06       Impact factor: 1.372

5.  Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Authors:  Yohei Mineharu; Neha Kamran; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Cancer Ther       Date:  2014-09-25       Impact factor: 6.261

Review 6.  New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Authors:  Victor Rodriguez-Freixinos; Katherine Karakasis; Amit M Oza
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

Review 7.  The impact of infection and tissue damage in solid-organ transplantation.

Authors:  Anita S Chong; Maria-Luisa Alegre
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 8.  Translational control of immune responses: from transcripts to translatomes.

Authors:  Ciriaco A Piccirillo; Eva Bjur; Ivan Topisirovic; Nahum Sonenberg; Ola Larsson
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

9.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

Review 10.  Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Authors:  Dudley W Lamming; Lan Ye; David M Sabatini; Joseph A Baur
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.